RU2011137486A - Аберрантная митохондриальная днк, ассоциированные с ней слитые транскрипты, продукты трансляции и гибрадизационные зонды - Google Patents

Аберрантная митохондриальная днк, ассоциированные с ней слитые транскрипты, продукты трансляции и гибрадизационные зонды Download PDF

Info

Publication number
RU2011137486A
RU2011137486A RU2011137486/10A RU2011137486A RU2011137486A RU 2011137486 A RU2011137486 A RU 2011137486A RU 2011137486/10 A RU2011137486/10 A RU 2011137486/10A RU 2011137486 A RU2011137486 A RU 2011137486A RU 2011137486 A RU2011137486 A RU 2011137486A
Authority
RU
Russia
Prior art keywords
cancer
mitochondrial
antibody
protein
acid sequence
Prior art date
Application number
RU2011137486/10A
Other languages
English (en)
Russian (ru)
Inventor
Райан ПАРР
Габриэль ДАКУБО
Эндрю ХАРБОТТЛ
Брайен РЕГЮЛИ
Дженнифер КРИД
Керри РОБИНСОН
Даниель КЛЯЙН
Original Assignee
Митомикс Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CA2009/000351 external-priority patent/WO2009117811A1/en
Application filed by Митомикс Инк. filed Critical Митомикс Инк.
Publication of RU2011137486A publication Critical patent/RU2011137486A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B10/00—Instruments for taking body samples for diagnostic purposes; Other methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determination; Throat striking implements
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y106/00—Oxidoreductases acting on NADH or NADPH (1.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Surgery (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
RU2011137486/10A 2009-03-27 2010-03-29 Аберрантная митохондриальная днк, ассоциированные с ней слитые транскрипты, продукты трансляции и гибрадизационные зонды RU2011137486A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CAPCT/CA2009/000351 2009-03-27
PCT/CA2009/000351 WO2009117811A1 (en) 2008-03-28 2009-03-27 Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor
PCT/CA2010/000423 WO2010115261A1 (en) 2009-03-27 2010-03-29 Aberrant mitochondrial dna, associated fusion transcripts and translation products and hybridization probes therefor

Publications (1)

Publication Number Publication Date
RU2011137486A true RU2011137486A (ru) 2013-05-10

Family

ID=42937093

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2011137486/10A RU2011137486A (ru) 2009-03-27 2010-03-29 Аберрантная митохондриальная днк, ассоциированные с ней слитые транскрипты, продукты трансляции и гибрадизационные зонды

Country Status (6)

Country Link
EP (2) EP3272871B1 (https=)
JP (1) JP5734947B2 (https=)
KR (1) KR101720555B1 (https=)
AU (1) AU2010234238B2 (https=)
RU (1) RU2011137486A (https=)
WO (1) WO2010115261A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2719718C (en) 2008-03-28 2019-07-02 Mdna Life Sciences Inc. Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor
TWI709188B (zh) 2018-09-27 2020-11-01 財團法人工業技術研究院 基於機率融合的分類器、分類方法及分類系統
CN113025633B (zh) * 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5807522A (en) 1994-06-17 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods for fabricating microarrays of biological samples
US6218117B1 (en) * 1998-06-15 2001-04-17 Mitokor Compositions and methods for identifying agents that quantitatively alter detectable extramitochondrial DNA:mitochondrial DNA ratios
JP2005506057A (ja) * 2001-06-11 2005-03-03 １３０４８５４ オンタリオ・リミテッド 健康科学のための診断ツールとしての全ミトコンドリアゲノム配列
US20030162174A1 (en) * 2001-06-11 2003-08-28 Sutherland John W. Detecting nucleic acid deletion sequences
EP1877559B1 (en) * 2005-04-18 2010-10-13 Mitomics Inc. Mitochondrial mutations and rearrangements as a diagnostic tool for the detection of sun exposure, prostate cancer and other cancers
CA2700941A1 (en) * 2007-09-26 2009-04-02 Genesis Genomics Inc. 3.4 kb mitochondrial dna deletion for use in the detection of cancer
CA2719718C (en) * 2008-03-28 2019-07-02 Mdna Life Sciences Inc. Aberrant mitochondrial dna, associated fusion transcripts and hybridization probes therefor

Also Published As

Publication number Publication date
JP5734947B2 (ja) 2015-06-17
KR101720555B1 (ko) 2017-03-29
AU2010234238B2 (en) 2016-07-28
EP2411522B1 (en) 2017-09-06
KR20140014360A (ko) 2014-02-06
JP2012521745A (ja) 2012-09-20
EP2411522A1 (en) 2012-02-01
EP3272871B1 (en) 2020-01-15
EP3272871A1 (en) 2018-01-24
WO2010115261A1 (en) 2010-10-14
AU2010234238A1 (en) 2011-09-29
EP2411522A4 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
RU2014108048A (ru) Способ обнаружения рака поджелудочной железы
JP5671475B2 (ja) 方法
WO2012040168A2 (en) Biomarkers for differentiating melanoma from benign nevus in the skin
JP2019518452A5 (https=)
ES2659798T3 (es) Detección de la restricción de cadena ligera de inmunoglobulina por hibridación in situ de ARN
JO3812B1 (ar) أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1)
MX357292B (es) Método para detectar cáncer.
ES2608313T3 (es) Identificación de resistencia antibiótica en microorganismos
US20210318310A1 (en) Methods for monitoring polymorphonuclear myeloid derived suppressor cells
KR20170104518A (ko) 크기에 기초한 희귀 세포의 회수를 위한 칼럼 기반 장치 및 방법, 및 이의 용도
KR101333207B1 (ko) 자궁내막증과 연관된 유전자 마커 및 이의 용도
RU2011137486A (ru) Аберрантная митохондриальная днк, ассоциированные с ней слитые транскрипты, продукты трансляции и гибрадизационные зонды
WO2017125892A3 (es) Anticuerpos monoclonales específicos para el antígeno piii de adenovirus humano (adv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por adv
RU2008129770A (ru) Новый ассоциированный с раком антиген
Kosa et al. Comparison of dual-color dual-hapten brightfield in situ hybridization (DDISH) and fluorescence in situ hybridization in breast cancer HER2 assessment
KR101182974B1 (ko) 림프종 진단 또는 예후 마커로서 Ｐｅｌｌｉｎｏ 1
CN107904307B (zh) Nfi转录因子在食管鳞癌中的应用
CN111944821B (zh) 一种结肠癌核酸适体的组织样本快速筛选及其在检测制剂中的应用
CN119265302A (zh) 用于诊断肝癌的生物标志物组合、Logistics模型及其应用
WO2023244680A3 (en) Reagents and methods for cell identification and characterization
JP2012521745A5 (https=)
CN104611441A (zh) 一种检测所有11种衣原体的定量pcr的引物、探针及试剂盒
CN104531878B (zh) 一种联合lncRNA和AR3检测试剂盒及应用
CN121426957B (zh) 一种抗Nectin-4蛋白单克隆抗体及其相关产品和用途
JP4887505B2 (ja) 癌の転移性及び浸潤能の検査方法

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20140812